Authors : Sarra Azzez; Hela Zouaghi; Chaima Ben Haj Hassine; Chiraz Baccouche

Volume/Issue : Volume 11 - 2026, Issue 10 - October

Google Scholar : https://tinyurl.com/yutnktn8

DOI : https://doi.org/10.38124/ijisrt/26Oct1163

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Pemphigus vulgaris (PV) is a rare autoimmune blistering disease of the skin and mucous membranes. The oral cavity is frequently the first, and sometimes the only, site involved, and crusted or erosive lesions may be mistaken for malignancy. A 70-year-old woman in good general health was referred for crusted lesions on an erythematous background involving the entire lower lip and its inner surface, highly suspicious of malignancy. An erosive plaque of the right buccal mucosa, measuring 2 cm along its longest axis, with raised borders and surrounding erythema, had been evolving for 3 months. No other cutaneous site was involved, and the Nikolsky sign was positive. Biopsies of two lesions were performed. Histopathology and direct immunofluorescence (DIF) were consistent with pemphigus vulgaris. The patient received local prednisone 20 mg daily together with topical treatment of the labial lesions. Marked clinical improvement was observed after 2 months of treatment. Lessons. Severe crusted lip lesions in an older adult can present as PV rather than carcinoma. Early biopsy with DIF, and attention to a positive Nikolsky sign, allow prompt diagnosis and treatment of an otherwise misleading presentation.

Keywords : Pemphigus Vulgaris; Oral Pemphigus; Lip Lesions; Oral Squamous Cell Carcinoma; Differ; Corticosteroids; Case Report.

References :

1. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255-70.
2. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-94.
3. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.
4. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869-77.
5. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40(2 Pt 1):167-70.
6. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med. 2002;13(5):397-408.
7. Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):349-55.
8. Scully C, Mignogna M. Oral mucosal disease: pemphigus. Br J Oral Maxillofac Surg. 2008;46(4):272-7.
9. Mignogna MD, Lo Muzio L, Bucci E. Clinical features of gingival pemphigus vulgaris. J Clin Periodontol. 2001;28(5):489-93.
10. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges. 2011;9(10):844-56.
11. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729-35.
12. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-32.
13. Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170-201.
14. Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 guideline for diagnosis and treatment, guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405-14.
15. Joly P, Horvath B, Patsatsi O, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-13.
16. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-40.
17. Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384(24):2295-305.
18. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366(9479):61-73.
19. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996;132(2):203-12.